Get started
Author

Hiroyuki Ugai

Observed name: H. Ugai
Institution: MSD K.K. (Japan)
OpenAlex ID: A5079136395
Restricted mean survival time as a summary measure of time‐to‐event outcome
2020 · Takahiro Hasegawa, Saori Misawa, et al. · Pharmaceutical Statistics · 54
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE ‐826
2022 · Shin Nishio, Kan Yonemori, et al. · Cancer Science · 36
PDF
Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial
2020 · Masataka Kuwana, Takashi Ogura, et al. · Modern Rheumatology · 26
PDF
A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19
2022 · Keisuke Nakamura, Katsukuni Fujimoto, et al. · Clinical and Translational Science · 19
Pharmacokinetics of Single Doses of BI 425809 in Healthy Chinese and Japanese Subjects: A Randomized Study
2019 · Yasuhiro Tsuda, Hiroyuki Ugai, et al. · Clinical Therapeutics · 15
Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial
2021 · Yoshikazu Inoue, Takafumi Suda, et al. · Respiratory Medicine · 14
PDF
The efficacy and long-term safety of a triple combination of 80 mg telmisartan, 5 mg amlodipine and 12.5 mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extension
2016 · Jitsuo Higaki, Issei Komuro, et al. · Hypertension Research · 10
PDF
Phase I dose escalation (esc) trial of weekly intravenous (i.v.) BI 836845 in Japanese patients (pts) with advanced solid tumors
2016 · T. Doi, K. Shitara, et al. · Annals of Oncology · 2
O14-1 Pembrolizumab + chemotherapy in Japanese patients with persistent, recurrent, or metastatic cervical cancer: KEYNOTE-826
2022 · Kan Yonemori, Shin Nishio, et al. · Annals of Oncology
PDF
タイムツーイベント結果の要約尺度としての制限平均生存時間【jst・京大機械翻訳】
2020 · Takahiro Hasegawa, Misawa Saori, et al.
本態性高血圧症の日本人患者に対するテルミサルタン80mg,アムロジピン5mg,およびヒドロクロロチアジド12.5mgの3剤併用療法の有効性および長期安全性:ランダム化二重盲検試験と続く長期オープン試験
2017 · Higaki Jitsuo, Issei Komuro, et al. · Hypertension Research
Open‐label phase 2 study of faldaprevir, deleobuvir and ribavirin in Japanese treatment‐naive patients with chronic hepatitis C virus genotype 1 infection
2015 · Hiroshi Yatsuhashi, Nobuyoshi Kodani, et al. · Hepatology Research
PDF
Works count: 12
Citation count: 176
H-index: 7
I10-index: 7
Year
Topic
Type